US › Healthcare

Jasper Therapeutics Inc (JSPR)

US · Healthcare · Biotechnology

$0.67+9.76%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-1.2M
Profit YoY
+94.5%
EPS
$-0.38
EPS estimate
$-0.54

EPS came in at -0.38 against a street estimate of -0.54 — a beat of 29.6%.

Key statistics

Market cap
$21.0M
Forward P/E
0.0
P/B
6.17
Book value
$0.12
EPS (TTM)
$-2.58
52-week high
$3.14
52-week low
$0.32
50-day MA
$0.60
200-day MA
$1.26
Beta
3.07

Analyst view

Analysts rate Jasper Therapeutics Inc a strong buy (11 buy, 0 hold, 0 sell out of 11) with an average price target of $9.17.

Shareholding

Insiders
2.56%
Institutions
47.62%

Largest institutional holders

FundStake
Velan Capital Investment Management LP8.02%
Millennium Management LLC4.86%
Kingdon Capital Management LLC4.06%
Morgan Stanley - Brokerage Accounts4.01%
Vanguard Capital Management, LLC3.52%
Rock Springs Capital Management LP3.31%
The Carlyle Group Inc3.20%
BOOTHBAY FUND MANAGEMENT, LLC1.75%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Jasper Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.